Evidence map›Paper›PMID 26961805›Full record

ArticleActa biomaterialia2016

A novel platelet lysate hydrogel for endothelial cell and mesenchymal stem cell-directed neovascularization.

Scott T Robinson, Alison M Douglas, Tatiana Chadid, Katie Kuo, Ajai Rajabalan, Haiyan Li, Ian B Copland, Thomas H Barker, Jacques Galipeau, Luke P Brewster

Open access · greenAbstract read
In one paragraph

Article in Acta biomaterialia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 87 citations in OpenAlex.

  1. Article
  2. Dual ROS modulation by MnOTheranostics · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Therapeutic Biomaterial Approaches to Alleviate Chronic Limb Threatening Ischemia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Scott T RobinsonEmory University, Department of Surgery, Atlanta, GA 30322, USA.
Alison M DouglasWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30322, USA.
Tatiana ChadidEmory University, Department of Surgery, Atlanta, GA 30322, USA.
Katie KuoEmory University, Department of Surgery, Atlanta, GA 30322, USA.
Ajai RajabalanEmory University, Department of Surgery, Atlanta, GA 30322, USA.
Haiyan LiEmory University, Department of Surgery, Atlanta, GA 30322, USA.
Ian B CoplandEmory University, Department of Hematology and Oncology, Winship Cancer Institute, Atlanta, GA 30322, USA.
Thomas H BarkerWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30322, USA.
Jacques GalipeauEmory University, Department of Hematology and Oncology, Winship Cancer Institute, Atlanta, GA 30322, USA.
Luke P BrewsterEmory University, Department of Surgery, Atlanta, GA 30322, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30322, USA; Atlanta Veterans Affairs Medical Center, Surgical and Research Services, Decatur, GA 30030, USA. Electronic address: lbrewst@emory.edu.
Emory University · USGeorgia Institute of Technology · US

Funding

Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Engineering fibrin polymers for enhanced angiogenesisR01EB011566 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI BARKER, THOMAS HARRISON · 2010 to 2013
$1.5M
Molecular Mechanism of Disturbed Flow in Arterial StiffeningK08HL119592 · NHLBI · EMORY UNIVERSITY · PI BREWSTER, LUKE PACKARD · 2014 to 2018
$690k
NCATS NIH HHS UL1 TR000454NHLBI NIH HHS K08 HL119592NIBIB NIH HHS R01 EB011566
6 · The paper itself

Abstract

unlabelledMesenchymal stem cells (MSC) hold promise in promoting vascular regeneration of ischemic tissue in conditions like critical limb ischemia of the leg. However, this approach has been limited in part by poor cell retention and survival after delivery. New biomaterials offer an opportunity to localize cells to the desired tissue after delivery, but also to improve cell survival after delivery. Here we characterize the mechanical and microstructural properties of a novel hydrogel composed of pooled human platelet lysate (PL) and test its ability to promote MSC angiogenic activity using clinically relevant in vitro and in vivo models. This PL hydrogel had comparable storage and loss modulus and behaved as a viscoelastic solid similar to fibrin hydrogels despite having 1/4-1/10th the fibrin content of standard fibrin gels. Additionally, PL hydrogels enabled sustained release of endogenous PDGF-BB for up to 20days and were resistant to protease degradation. PL hydrogel stimulated pro-angiogenic activity by promoting human MSC growth and invasion in a 3D environment, and enhancing endothelial cell sprouting alone and in co-culture with MSCs. When delivered in vivo, the combination of PL and human MSCs improved local tissue perfusion after 8days compared to controls when assessed with laser Doppler perfusion imaging in a murine model of hind limb ischemia. These results support the use of a PL hydrogel as a scaffold for MSC delivery to promote vascular regeneration. STATEMENT OF SIGNIFICANCE: Innovative strategies for improved retention and viability of mesenchymal stem cells (MSCs) are needed for cellular therapies. Human platelet lysate is a potent serum supplement that improves the expansion of MSCs. Here we characterize our novel PL hydrogel's desirable structural and biologic properties for human MSCs and endothelial cells. PL hydrogel can localize cells for retention in the desired tissue, improves cell viability, and augments MSCs' angiogenic activity. As a result of these unique traits, PL hydrogel is ideally suited to serve as a cell delivery vehicle for MSCs injected into ischemic tissues to promote vascular regeneration, as demonstrated here in a murine model of hindlimb ischemia.

Indexed as

Neovascularization, PhysiologicAnimalsBlood PlateletsCells, ImmobilizedCoculture TechniquesDisease Models, AnimalEndothelial CellsFemaleHeterograftsHindlimbHumansHydrogelsIschemiaMaleMesenchymal Stem CellsMesenchymal Stem Cell TransplantationHydrogelsAngiogenesisCell ScaffoldCellular therapyMesenchymal stem cellPlatelet lysate

Identifiers

PMID26961805
PMCPMC4846562
OpenAlexW2290962415

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.